Clinical Research Unit, Begin Military Hospital, Saint-Mandé.
Department of Pathology, Henri Mondor Hospital, Créteil.
Anticancer Drugs. 2022 Jan 1;33(1):e720-e723. doi: 10.1097/CAD.0000000000001139.
Histological transformation into squamous cell carcinoma (SCC) is a rare mechanism of resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. Its pathophysiology remains unclear and its management is particularly challenging. We report on tumor progression with SCC histological transformation associated with the T790M mutation in a patient with stage IV bronchial adenocarcinoma with an L858R mutation of the EGFR gene and treated with gefitinib. We will discuss the importance of liquid and tumor biopsy in the diagnostic management of resistance mechanisms as well as therapeutic management options.
组织学转化为鳞状细胞癌（SCC）是表皮生长因子受体（EGFR）酪氨酸激酶抑制剂耐药的罕见机制。其病理生理学仍不清楚，其管理极具挑战性。我们报告了一例 T790M 突变相关的 SCC 组织学转化的肿瘤进展，该患者为 EGFR 基因 L858R 突变的 IV 期支气管腺癌，接受吉非替尼治疗。我们将讨论液体和肿瘤活检在耐药机制的诊断管理以及治疗管理选择中的重要性。
